Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA: AGN-151607 for Post-Operative Atrial Fibrillation
NCT03779841Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 2 trial of gemibotulinumtoxinA in Atrial fibrillation (AFib), sponsored by AbbVie Inc.. Started Mar 2019; status: completed.
02
Drugs
gemibotulinumtoxinA
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03779841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779841.